Vinayak et al. (2013) reported that FGF pathways have been implicated in breast tumorigenesis as a potential target for TNBC. In addition, there is some research indicating that it is related to breast cancer, as FGFR1 was found to be associated with luminal A breast cancer (Zou et al., 2016a). FGFR is also helpful in the targeted therapy of breast cancer (Ye et al., 2014). Amplification of FGFR1 also occurs in almost 10% of ER-positive breast cancers, particularly luminol type B breast cancer subtypes. In summary, FGFR1 and TNBC are closely related. This evidence concerns the gene FGFR1 and breast carcinoma.